Overweight and obesity. Overweight and obesity
Conditions
Interventions
Intervention 1: Intervention group1: Consume 3 capsules of Akkermansia muciniphila postbiotic supplement with count of 3×10^10 cell count daily for 12 weeks. Intervention 2: Intervention group 2:
Sponsors
Shiraz University
Eligibility
Sex/Gender
All
Age
20 Years to 50 Years
Inclusion criteria
Inclusion criteria: Not obese or overweight (body mass index above 25 kg/m2) Not obese due to known hormonal disorders Not intolerant to IBS IBD neuropathy, gastroparesis and gastrointestinal motility disorder No thyroid disorders, diabetes, kidney disease, rheumatoid arthritis, or migraine No antibiotics for 2 months prior to study entry No nutritional supplements, prebiotics, probiotics, and omega-3 for one month prior to study entry No planning for pregnancy within the next 6 months and no breastfeeding No history of hospitalization, surgery, or bariatric surgery from 3 months before the study to 6 months after entering the study. No weight change of more than 6 kg in the past 3 months
Exclusion criteria
Exclusion criteria: Planning for pregnancy for 6 months after the study Not having breast-feeding heavy alcohol use
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Body weight. Timepoint: At the beginning of the study (before the intervention) and the end of study (12 weeks after the intervention). Method of measurement: Scale.;Waist circumference. Timepoint: At the beginning of the study (before the intervention) and the end of study (12 weeks after the intervention). Method of measurement: Stadiometer. | — |
Secondary
| Measure | Time frame |
|---|---|
| Percent of body fat. Timepoint: At the beginning of the study (before the intervention) and the end of study (12 weeks after the intervention). Method of measurement: Body composition analyzer.;Lipopolysacchride (LPS). Timepoint: At the beginning of the study (before the intervention) and the end of study (12 weeks after the intervention). Method of measurement: Enzyme-linked immuno-sorbent (ELISA) assay.;High- sensitivity C-reactive Protein (hs-CRP). Timepoint: At the beginning of the study (before the intervention) and the end of study (12 weeks after the intervention). Method of measurement: Enzyme-linked immuno-sorbent (ELISA) assay.;Interleukin 6 (IL-6). Timepoint: At the beginning of the study (before the intervention) and the end of study (12 weeks after the intervention). Method of measurement: Enzyme-linked immuno-sorbent (ELISA) assay.;Interleukin 1-B (IL-1 B). Timepoint: At the beginning of the study (before the intervention) and the end of study (12 weeks after the intervention). Method of measurement: Enzyme-linked immuno-sorbent (ELISA) assay.;Leptin. Timepoint: At the beginning of the study (before the intervention) and the end of study (12 weeks after the intervention). Method of measurement: Enzyme-linked immuno-sorbent (ELISA) assay.;GLP-1. Timepoint: At the beginning of the study (before the intervention) and the end of study (12 weeks after the intervention). Method of measurement: Enzyme-linked immuno-sorbent (ELISA) assay.;Waist to hip ratio. Timepoint: At the beginning of the study (before the intervention) and the end of study (12 weeks after the intervention). Method of measurement: Flexible meter.;Visceral body fat. Timepoint: At the beginning of the study (before the intervention) and the end of study (12 weeks after the intervention). Method of measurement: Body composition analyzer.;Lean body mass. Timepoint: At the beginning of the study (before the intervention) and the end of study (12 weeks after the intervention). Method of measurem | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSanaz Rowshanzadeh
Shiraz University
Outcome results
None listed